Copyright
©2013 Baishideng Publishing Group Co.
World J Gastroenterol. Nov 28, 2013; 19(44): 7836-7845
Published online Nov 28, 2013. doi: 10.3748/wjg.v19.i44.7836
Published online Nov 28, 2013. doi: 10.3748/wjg.v19.i44.7836
Table 1 Summary of microRNAs significantly up-regulated in hepatitis C virus-induced hepatocellular carcinoma
| ncRNAs | Chromosomal location | Differential expression level | Clinical relevance | Ref. |
| Liver miRNAs | ||||
| miR-1269 | 4q13.2 | 15.7-fold, HCV-associated HCC (n = 9) vs normal livers (n = 12) and other liver diseases [HCV-associated cirrhosis (n = 10), HBV-associated accurate liver failure (n = 4)], P < 0.05 | Potential therapeutic target molecule to prevent HCV-induced HCC | [32] |
| miR-224 | Xq28 | 10.7-fold, HCV-associated HCC (n = 9) vs normal livers (n = 12) and other liver diseases [HCV-associated cirrhosis (n = 10), HBV-associated accurate liver failure (n = 4)], P < 0.05 | Potential therapeutic target molecule to prevent HCV-induced HCC | [32] |
| miR-452 | Xq28 | 10.1-fold, HCV-associated HCC (n = 9) vs normal livers (n = 12) and other liver diseases [HCV-associated cirrhosis (n = 10), HBV-associated accurate liver failure (n = 4)], P < 0.05 | Potential therapeutic target molecule to prevent HCV-induced HCC | [32] |
| miR-224-3p | Xq28 | 8.1-fold, HCV-associated HCC (n = 9) vs normal livers (n = 12) and other liver diseases [HCV-associated cirrhosis (n = 10), HBV-associated accurate liver failure ( = 4)], P < 0.05 | Potential therapeutic target molecule to prevent HCV-induced HCC | [32] |
| miR-221 | Xp11.3 | 3.7-fold, HCV-associated HCC (n = 9) vs normal livers (n = 12) and other liver diseases [HCV-associated cirrhosis (n = 10), HBV-associated accurate liver failure (n = 4)], P < 0.05 | Potential therapeutic target molecule to prevent HCV-induced HCC | [32] |
| miR-122 | 18q21.31 | > 2-fold, HCV-associated HCC (n = 43) vs normal livers (n = 3), P < 0.01; HCV associated dysplastic nodules (n = 9) normal livers (n = 3), P < 0.05 | Potential therapeutic target molecule to prevent HCV-induced HCC | [30] |
| miR-100 | 11q24.1 | > 2-fold, HCV-associated HCC (n = 43) vs normal livers (n = 3); HCV associated dysplastic nodules (n = 9) vs normal livers (n = 3) | Potential therapeutic target molecule to prevent HCV-induced HCC | [30] |
| miR-10a | 17q21.32 | > 2-fold, HCV-associated HCC (n = 43) vs normal livers ( = 3); HCV associated dysplastic nodules (n = 9) vs normal livers (n = 3) | Potential therapeutic target molecule to prevent HCV-induced HCC | [30] |
| Urinary miRNAs | ||||
| miR-625 | 14q23.3 | > 3-fold, HCV-associated HCC (n = 32) vs normal urine samples ( = 12), P < 0.05 | Potential marker for the detection/early diagnosis of HCC among high-risk HCV patients | [33] |
| miR-532 | Xp11.23 | > 3-fold, HCV-associated HCC (n = 32) vs normal urine samples ( = 12), P < 0.05 | Potential marker for the detection/early diagnosis of HCC among high-risk HCV patients | [33] |
| miR-618 | 12q21.31 | > 3-fold, HCV-associated HCC (n = 32) vs normal urine samples (n = 12), P < 0.05 | Potential marker for the detection/early diagnosis of HCC among high-risk HCV patients | [33] |
Table 2 Summary of microRNAs down-regulated in hepatitis C virus-induced hepatocellular carcinoma
| ncRNAs | Chromosomal location | Differential expression level | Clinical relevance | References |
| Liver miRNAs | ||||
| miR-199a-5p | 19q13.3 | 7.2-fold, HCV-associated HCC (n = 9) vs normal livers (n = 12) and other liver diseases [HCV-associated cirrhosis (n = 10), HBV-associated accurate liver failure (n = 4)], P < 0.05 | Potential therapeutic target molecule to prevent HCV-induced HCC | [32] |
| miR-199a-3p | 19q13.3 | 6.9-fold, HCV-associated HCC (n = 9) vs normal livers (n = 12) and other liver diseases [HCV-associated cirrhosis (n = 10), HBV-associated accurate liver failure (n = 4)], P < 0.05 | Potential therapeutic target molecule to prevent HCV-induced HCC | [32] |
| miR-199b-3p | 19q13.3 | 6.2-fold, HCV-associated HCC (n = 9) vs normal livers (n = 12) and other liver diseases [HCV-associated cirrhosis (n = 10), HBV-associated accurate liver failure (n = 4)], P < 0.05 | Potential therapeutic target molecule to prevent HCV-induced HCC | [32] |
| miR-214 | 1q24.3 | 5.5-fold, HCV-associated HCC (n = 9) vs normal livers (n = 12) and other liver diseases [HCV-associated cirrhosis (n = 10), HBV-associated accurate liver failure (n = 4)], P < 0.05 | Potential therapeutic target molecule to prevent HCV-induced HCC | [32] |
| miR-198 | 19p13.3 | Approximately 5-fold, HCV-associated HCC (n = 43) vs normal livers (n = 3), P < 0.01; HCV-associated Dysplastic nodules (n = 9) vs normal livers (n = 3), P < 0.01 | Potential therapeutic target molecule to prevent HCV-induced HCC | [30] |
| miR-139-3p | 11q13.4 | 4.6-fold, HCV-associated HCC (n = 9) vs normal livers (n = 12) and other liver diseases [HCV-associated cirrhosis (n = 10), HBV-associated accurate liver failure (n = 4)], P < 0.05 | Potential therapeutic target molecule to prevent HCV-induced HCC | [32] |
| miR-139-5p | 11q13.4 | 4.4-fold, HCV-associated HCC (n = 9) vs normal livers (n = 12) and other liver diseases [HCV-associated cirrhosis (n = 10), HBV-associated accurate liver failure (n = 4)], P < 0.05 | Potential therapeutic target molecule to prevent HCV-induced HCC | [32] |
| miR-424-3p | Xq26.3 | 3.9-fold, HCV-associated HCC (n = 9) vs normal livers (n = 12) and other liver diseases [HCV-associated cirrhosis (n = 10), HBV-associated accurate liver failure (n = 4)], P < 0.05 | Potential therapeutic target molecule to prevent HCV-induced HCC | [32] |
| miR-125a-5p | 19q13 | 3.7-fold, HCV-associated HCC (n = 9) vs normal livers (n = 12) and other liver diseases [HCV-associated cirrhosis (n = 10), HBV-associated accurate liver failure (n = 4)], P < 0.05 | Potential therapeutic target molecule to prevent HCV-induced HCC | [32] |
| miR-130a | 11q12.1 | 2.9-fold, HCV-associated HCC (n = 9) vs normal livers (n = 12) and other liver diseases [HCV-associated cirrhosis (n = 10), HBV-associated accurate liver failure (n = 4)], P < 0.05 | Potential therapeutic target molecule to prevent HCV-induced HCC | [32] |
| miR-145 | 5q32 | > 2-fold; HCV-associated HCC (n = 43) vs normal livers (n = 3); HCV associated dysplastic nodules (n = 9) vs normal livers (n = 3) | Potential therapeutic target molecule to prevent HCV-induced HCC | [30] |
| Urinary miRNAs | ||||
| miR-516-5p | 19q13.42 | > 3-fold, HCV-associated HCC (n = 32) vs normal urine samples (n = 12), P < 0.05 | Potential marker for early diagnosis of HCC among high-risk HCV patients | [33] |
| miR-650 | 22q11.22 | > 3-fold, HCV-associated HCC (n = 32) vs normal urine samples (n = 12), P < 0.05 | Potential marker for early diagnosis of HCC among high-risk HCV patients | [33] |
- Citation: Hou W, Bonkovsky HL. Non-coding RNAs in hepatitis C-induced hepatocellular carcinoma: Dysregulation and implications for early detection, diagnosis and therapy. World J Gastroenterol 2013; 19(44): 7836-7845
- URL: https://www.wjgnet.com/1007-9327/full/v19/i44/7836.htm
- DOI: https://dx.doi.org/10.3748/wjg.v19.i44.7836